Forty Seven Inc. has $75m in Series A venture capital and something else that's pretty novel for a startup biotechnology company: an immuno-oncology development program that's already in the clinic with data expected later this year.
Palo Alto, California-based Forty Seven made a big bet on lead therapeutic candidate Hu5F9-G4 and the cancer treatment's target by...